Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab SC vs IV in Healthy Participants
NCT06713590Phase 1Completed
- Sponsor
- Incyte
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (4 arms), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Axatilimab, Area Under the Plasma Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) and 2 more. Started Jan 2025; status: completed.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06713590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713590.